People on the Move
Scilex
Scilex Pharmaceuticals, which develops pain therapies, has appointed two industry veterans to its board.
Jerrold Sendrow brings a 28-year career in accounting and finance. He previously worked as VP and Chief Financial Officer at 800 Travel Systems, as VP of Finance at MSW Columbia Travel Group, and Controller at PISA Brothers.
Eric Floyd, who also joins the board, has sixteen years of experience in product development and regulatory matters at Novartis, Bristol Myers Squibb, Hospira, and Cephalon. Floyd is currently VP of US Regulatory Affairs and Clinical Quality Assurance for Lundbeck, and holds a PhD in Neurophysiology from Meharry Medical College and an executive MBA from Saint Joseph's University and has served as Assistant Professor at Harvard University School of Medicine.
Scilex is presently working on Ztilido (a 1.8% lidocaine patch) for the treatment of post-shingles pain. The company has expressed its hope to capitalise on what it estimates is the “$1.25bn market” to be created when the US patent on Lidoderm (owned by Endo) expires next year.
